Reduced activity of B lymphocytes, recognised by Sysmex XN-2000\u2122 haematology analyser, predicts mortality in patients with coronavirus disease 2019 by Rolla, R. et al.
Int J Lab Hematol. 2020;00:1–4. wileyonlinelibrary.com/journal/ijlh   |  1© 2020 John Wiley & Sons Ltd
 
Received: 7 July 2020  |  Revised: 28 July 2020  |  Accepted: 7 August 2020
DOI: 10.1111/ijlh.13331  
L E T T E R  T O  T H E  E D I T O R
Reduced activity of B lymphocytes, recognised by Sysmex  
XN-2000™ haematology analyser, predicts mortality in patients 
with coronavirus disease 2019
Dear Editors,
Coronavirus disease 2019 (COVID-19) has severely tested health-
care systems around the world. There is an urgent need not only 
to identify effective treatments and to develop a vaccine but also 
to identify clinical and laboratory predictors of disease progression 
towards serious and fatal forms. Currently, recent evidence outlines 
the role played by the immune system in combating severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its 
clinical manifestations.1
In this study, we evaluated the discriminatory ability in predict-
ing mortality of a series of clinical, haematological and biochemical 
parameters at hospital admission in patients who tested positive for 
SARS-CoV-2 at nasopharyngeal swab and developed COVID-19 that 
required hospitalisation. We included 183 COVID-19 consecutive 
cases, admitted to an Academic hospital during the first month of 
the epidemic in Northern Italy, from 6 to 31 March. Patients were 
observed until death or hospital discharge and the laboratory param-
eters were evaluated at different timing during hospitalisation, but 
only the data at admission, of “naive” patients, before the starting of 
any therapy, are reported.
In-hospital mortality rate was 17%. Demographic, clinical, hae-
matological and biochemical parameters at admission are described 
in Table 1, and predictors of in-hospital mortality are presented in 
Table 2. Among demographic and clinical characteristics, in-hospi-
tal mortality was associated with age (OR 1.09; 95% CI 1.05-1.13, 
P < .001), pre-existing diabetes (OR 2.80; 95% CI 1.22-6.42, P = .015), 
arterial hypertension (OR 3.03; 95% CI 1.35-6.78, P = .007), cardio-
vascular disease (OR 5.29; 95% CI 2.34-11.96, P < .001) and kidney 
disease (OR 5.42; 95% CI 2.16-13.58, P < .001) at univariate analysis 
(Table 2).
Regarding biochemical parameters, C-reactive protein and cre-
atinine values were significantly associated with a fatal form of 
COVID-19 at univariate analysis (OR 1.10; 95% 1.03-1.17, P = .004; 
OR 5.70; 95% 2.53-12.84, P < .001, respectively) (Table 2).2
At admission, not all haematological parameters were signifi-
cantly different between nonsurvivors and survivors. In particular, 
median peripheral total blood leucocyte and lymphocyte counts 
were slightly but not significantly different (Table 2), confirming that 
during the early phase of the disease, when nonspecific symptoms 
are present, peripheral blood leucocyte and lymphocyte counts 
cannot be considered predictors of an unfavourable outcome.3,4 
Nevertheless, nonsurvivors, as compared with survivors, presented 
significantly lower absolute platelet counts (148 vs. 186 x 103/µl; 
P = .005) (Table 2). Furthermore, RDW-CV (OR 1.21; 95% CI 1.06-
1.38, P = .005), mean platelet volume (OR 2.74; 95% CI 1.76-4.26, 
P < .001) and platelet large cell ratio (OR 1.14; 95% CI 1.07-1.20, 
P < .001) resulted associated with mortality at univariate analysis 
(Table 1).3-5
The analyser used for the blood count test in the present study, 
Sysmex XN-2000™ Haematology System (Sysmex), is also able to 
determine a series of parameters that provide quantitative and qual-
itative information on the inflammatory response of the patient's 
immune system, specifically regarding the activation status of neu-
trophils (neutrophil reactivity intensity: NEUT-RI; neutrophil granu-
larity intensity: NEUT-GI) and of lymphocytes (reactive lymphocytes: 
RE-LYMP; antibody-synthesising lymphocytes: AS-LYMP). These 
“extended inflammation parameters” are measured in the WBC dif-
ferential (WDF) channel according to their cell membrane composi-
tion and cytoplasmic activity (RNA content) and become diagnostic 
reportable parameters with the XN software version 21.12.
Typically, activated neutrophils (increased NEUT-RI, increased 
NEUT-GI), immature granulocytes (IG), reactive lymphocytes (RE-
LYMP) and T cell-independent plasma cells (AS-LYMP) are found in 
the initial, nonspecific phase of infection.5,6 These cells are quan-
tified in the WDF channel according to their cell membrane com-
position and cytoplasmic activity (RNA content). In particular, total 
reactive lymphocytes (RE-LYMP) include activated B and T lympho-
cytes, recognised by an increased fluorescence intensity on XN-
2000™ (Sysmex), compared to that of not activated lymphocytes, 
while the antibody-synthesising lymphocytes (AS-LYMP) are exclu-
sively activated B lymphocytes, recognised by the markedly high in-
crease of fluorescence intensity compared to that of not activated 
lymphocytes. Even though our data about AS-LYMP were not sub-
sequently confirmed by immunophenotyping, the strong correlation 
of these high fluorescence lymphocytes determined by Sysmex anal-
ysers with peripheral plasma cells or activated B lymphocytes identi-
fied by immuno-flow cytometry method has been shown in previous 
studies.7,8 Therefore, the combination of the RE-LYMP and AS-LYMP 
parameters provides additional information regarding the cellular 
activation of the innate and adaptive immune response.
In our series, RE-LYMP and AS-LYMP counts at hospital admis-
sion were significantly lower in nonsurvivors, as compared with 
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survivors (Table 2). Moreover, the AS-LYMP count was significantly 
associated with mortality at univariate analysis (OR 0.005; 95% CI 
0.00-0.01, P = .017) (Table 2).
Finally, at multivariate regression analysis, among demographic 
and clinical characteristics, the only independent predictors of in-hos-
pital mortality due to COVID-19 were age (OR 1.04; 95% CI 1.00-1.09, 
P = .030), C-reactive protein (OR 1.10; 95% 1.01-1.20, P = .022), creat-
inine (OR 2.76; 95% 1.07-7.08, P = .035) and the AS-LYMP count (OR 
0.005; 95% CI 0.00-0.01, P = .021) (Table 2).9 Moreover, analysis of the 
receiver operating characteristic (ROC) curve showed that basal AS-
LYMP displayed significantly high diagnostic accuracy for in-hospital 
mortality (AUC 0.662, 95% CI 0.562-0.763, P = .009). The statistical 
best cut-off for predicting in-hospital mortality, calculated by Youden's 
index, was 0.025, with sensitivity (Sn) = 0.81 and specificity (Sp) = 0.48.
In summary, older age, high C-reactive protein, impaired renal 
function and decreased count of activated B lymphocytes at hospi-
tal admission independently predicted risk of mortality in our series. 
As confirming the previously reported impact of age in determining 
the in-hospital mortality among patients with COVID-19,9 we em-
phasized the role of simply evaluable parameter of impaired adaptive 
immune response in predicting an unfavourable outcome of SARS-
CoV-2 infection.
It is well known that the counts of leucocytes, neutrophils 
and lymphocytes help to discriminate between inflammation and 
TA B L E  1   Demographic, clinical and laboratory data of patients included in the study
Parameters Alive (no. 152) Dead (no. 31) P value
Age (years) 62 (51-73) 80 (74-85) <.001*
Male sex (no., %) 86 (57) 25 (81) .022*
Diabetes (no., %) 28 (18%) 12 (39%) .018*
Hypertension (no., %) 57 (38%) 20 (65%) .009*
CV disease (no., %) 35 (23%) 19 (61%) <.001*
Lung disease (no., %) 19 (13%) 8 (26%) .09
Renal disease (no., %) 14 (9%) 11 (36%) .001*
Liver disease (no., %) 5 (3%) 2 (7%) .338
WBC (×103 cells/µL) 5.75 (4.55-7.44) 6.32 (4.70-11.15) .138
Hb (g/dL) 13.50 (12.33-14.80) 13.10 (10.80-14.10) .064
RDW-CV (%) 13.20 (12.70-14.08) 14.50 (12.20-17-30) .001*
MPV (fL) 10.50 (9.90-11.00) 11.40 (10.70-12.10) <.001*
P-LCR (%) 28.5 (23.35-33.20) 35.90 (31.20-42.40) <.001*
PLT (×103 cells/µL) 186.50 (152.25-226.50) 148.00 (125.00-197.00) .005*
Neutrophils (×103 cells/ΜL) 4.06 (2.9-5.44) 4.60 (3.45-8.02) .058
Lymphocytes (×103 cells/ΜL) 1.08 (0.85-1.44) 0.85 (0.69-1.24) .093
Monocytes (×103 cells/ΜL) 0.45 (0.33-0.64) 0.45 (0.25-0.71) .602
Q-flag Blasts?/Abn lympho?* 40 (40-50) 40 (40-50) .817
Q-flag Left shift?* 0 (0-10) 0 (0-10) .678
Q-flag Atypical lympho?* 20 (10-20) 10 (0-20) .009*
Q-flag Fragments?* 0 (0-0) 0 (0-13) .021*
IG (×103 cells/µL) 0.02 (0.02-0.05) 0.03 (0.02-0.07) .234
HFLC (×103 cells/µL) 0.03 (0.01-0.05) 0.02 (0.01-0.04) .008*
AS-LYMP (×103 cells/µL) 0.02 (0.00-0.05) 0.00 (0.00-0.02) .007*
RE-LYMP (×103 cells/µL) 0.07 (0.04-0.10) 0.04 (0.03-0.08) .014*
NEUT-RI (FI) 47.30 (45.20-49.70) 46.90 (45.85-48.75) .779
NEUT-GI (SI) 151.30 (148.25-155.80) 152.00 (148.85-156.10) .677
CRP (mg/dL) 3.80 (2.24-8.74) 8.60 (5.71-15.06) .002*
Creatinine (mg/dL) 0.85 (0.69-1.02) 1.20 (0.91-1.94) <.001*
Note: Quantitative variables are expressed as median (interquartile range), while qualitative variables as absolute frequency and percentages.
Abbreviations: AS-LYMP, antibody-synthesizing lymphocytes; CRP, C-reactive protein; CV, cardiovascular; FI, fluorescence intensity; Hb, 
haemoglobin; HFLC, highly fluorescent lymphocyte cells; IG, immature granulocytes; IQR, interquartile range; MPV, mean corpuscular volume; 
NEUT-GI, neutrophil granularity intensity; NEUT-RI, neutrophil reactivity intensity; P-LCR, platelet large cell ratio; PLT, platelets; RDW-CV, red blood 
cell distribution width (coefficient of variation); RE-LYMP, reactive lymphocytes; SI, scatter intensity; WBC, white blood cells.
*In XN-2000, the probability of abnormal findings is indicated by the Q value, which is based on a scale from 0 to 300, with increments of 10 
arbitrary units. In our laboratory, the cut-off for flagging is set at 100. 
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infection, between the different pathogenic causes of infection (viral 
versus bacterial) and the different types of immune response (early 
innate, cellular or humoral). In particular, lymphocytosis and neutro-
philia are normally associated with viral and bacterial infections, re-
spectively, and, usually, the AS-LYMP of white blood cells (WBC) is 
higher in viral infections.5,6
In our COVID-19 nonsurvivors, the antibody-synthesising lym-
phocyte count was significantly lower, already at hospital admission, 
compared with survivors, suggesting an impaired B-cell humoral im-
mune response as the cause of a fatal outcome in COVID-19-infected 
patients. Therefore, the reduction of AS-LYMP seems to be an im-
portant indicator of severity and an independent predictor of mortal-
ity in critically ill COVID-19-infected patients. If confirmed in a larger 
population, these data might be relevant to researchers for a better 
understanding of the altered immunologic response in severely af-
fected patients and might become an important support to formulate 
Predictors of in-
hospital mortality
Univariate Regression Multivariate Regression
OR (95% CI) P value OR (95% CI) P value
Age 1.09 (1.05-1.13) <.001* 1.04 (1.00-1.09) .030*
Gender 3.20 (1.24-8.24) .016* .232
Diabetes 2.80 (1.22-6.42) .015* .119
Hypertension 3.03 (1.35-6.78) .007* .410
CV disease 5.29 (2.34-11.96) <.001* .506
Renal disease 5.42 (2.16-13.58) <.001* .744
Lung disease 2.44 (0.95-6.22) .063
Liver disease 2.03 (0.38-10.96) .412
WBC 1.05 (0.98-1.12) .178
Hb 0.834 (0.699-0.996) .045* .822
RDW-CV 1.21 (1.06-1.38) .005* .562
PLT 1.00 (0.99-1.00) .109
P-LCR 1.14 (1.07-1.20) <.001* .082
MPV 2.74 (1.76-4.26) <.001* .101
Neutrophils 1.15 (1.03-1.28) .012*
Lymphocytes 0.84 (0.44-1.61) .592
Monocytes 1.69 (0.83-3.46) .152
CRP 1.10 (1.03-1.17) .004* 1.10 (1.01-1.20) .022*




Q-flag Left shift? 0.99 (0.94-1.03) .534
Q-flag Atypical 
lympho?
0.97 (0.93-1.00) .046* .392
Q-flag Fragments? 1.00 (0.99-1.02) .735
IG 7.46 (0.16-348.21) .306
HFLC 0.00 (0.00-4.62) .076
AS-LYMP 0.00 (0.00-0.01) .017* 0.005 (0.00-0.01) .021*
RE-LYMP 0.02 (0.00-146.42) .395
NEUT-RI 0.98 (0.88-1.08) .640
NEUT-GI 1.01 (0.94-1.10) .729
Abbreviations: AS-LYMP, antibody-synthesizing lymphocytes; CRP, C-reactive protein; CV, 
cardiovascular; FI, fluorescence intensity; Hb, haemoglobin; HFLC, highly fluorescent lymphocyte 
cells; IG, immature granulocytes; IQR, interquartile range; MPV, mean corpuscular volume; 
NEUT-GI, neutrophil granularity intensity; NEUT-RI, neutrophil reactivity intensity; P-LCR, platelet 
large cell ratio; PLT, platelets; RDW-CV, red blood cell distribution width (coefficient of variation); 
RE-LYMP, reactive lymphocytes; SI, scatter intensity; WBC, white blood cells.
To facilitate data interpretation, the values in bold and with an asterisk identify the statistically 
significant results (P value ≤.05).
TA B L E  2   Univariate and multivariate 
regression for demographic, clinical and 
laboratory data
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a tailored treatment approach and promptly provide intensive care 
to those who are at greater risk of a fatal outcome in SARS-CoV-2 
infection.
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